Understanding advanced prostate cancer using mouse models
Preclinical analyses of advanced prostate cancer in genetically-engineered mice
['FUNDING_R01'] · COLUMBIA UNIVERSITY HEALTH SCIENCES · NIH-11258968
Researchers are learning how BRCA1 and BRCA2 changes drive aggressive prostate cancer using specially bred mice to help find better treatments for men with treatment‑resistant disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | COLUMBIA UNIVERSITY HEALTH SCIENCES (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11258968 on ClinicalTrials.gov |
What this research studies
This project uses genetically engineered mice that lose Brca1 or Brca2 in the prostate to replicate changes seen in men with advanced prostate cancer. The team studies how these changes cause fast‑growing, bone‑spreading tumors and how hormone (androgen) deprivation makes the disease worse. They combine the mouse experiments with computational tools, called OncoLoop, to match individual patient tumor profiles to the best mouse models and to predict drugs to test. The combined lab and computer approach aims to identify treatments targeted to specific molecular forms of aggressive prostate cancer.
Who could benefit from this research
Good fit: Men with advanced or treatment‑resistant prostate cancer, especially those whose tumors have BRCA1, BRCA2, or other DNA‑repair gene alterations, are the ideal candidates to benefit from this research.
Not a fit: Men with early‑stage prostate cancer, tumors without DNA‑repair defects, or those unable to provide genomic data or samples are less likely to gain direct benefit from these findings.
Why it matters
Potential benefit: If successful, this work could reveal drug matches or treatment strategies that better help men with BRCA-related or DNA‑repair–defective advanced prostate cancer.
How similar studies have performed: PARP inhibitors have helped some men with BRCA‑mutant prostate cancer and mouse models have guided such discoveries, though the patient‑to‑mouse matching platform used here is relatively new.
Where this research is happening
NEW YORK, UNITED STATES
- COLUMBIA UNIVERSITY HEALTH SCIENCES — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ABATE-SHEN, CORY — COLUMBIA UNIVERSITY HEALTH SCIENCES
- Study coordinator: ABATE-SHEN, CORY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.